Seattle-based biotech startup is currently in the process of a private placement offering which is expected to be completed in June. Venture capitalists Issac and David Blech are the principal financiers and Paine Webber is handling the placement. Founded in the fall of 1989, the company is headed by three major biotech execs: Chairman of the Board George Rathmann, PhD, (currently chairman of Amgen); President and CEO Robert Nowinski, PhD, (former VP Bristol Myers and founder of Genetics Systems); and Science Director Christopher Henney, PhD, (cofounder of Immunex). The company's focus will be the development of biotech and pharmaceutical therapeutics for the treatment of inflammatory diseases.
You may also be interested in...
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
During oral argument in the Arthrex case, several justices seemed to agree with the Federal Circuit that PTAB judges should have been appointed by the president. They could opt to get around the problem by enabling the PTO director to review all panel decisions.